Current Treatment Landscape for KRASG12C-Mutated NSCLC

Opinion
Video

Narjust Florez, MD, discusses KRAS G12C mutated non-small cell lung cancer, a subset of KRAS mutations which comprises 14% of NSCLC cases.

Recent Videos
4 experts in this video
4 experts in this video
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
4 experts in this video
4 experts in this video
Stage IV lung cancer may be curable based on the success of the DREAM Program, according to thoracic surgeon, Ankit Bharat, MBBS,
Related Content
The Oncomine Dx Express Test may generate results in as little as 24 hours when used on the Ion Torrent Genexus Dx Integrated Sequencer.

FDA OKs NGS Test for Tumor Profiling and as CDx for Sunvozertinib in NSCLC

Roman Fabbricatore
July 7th 2025
Article

The Oncomine Dx Express Test may generate results in as little as 24 hours when used on the Ion Torrent Genexus Dx Integrated Sequencer.

Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

Stephen V. Liu, MD;Joshua K. Sabari, MD
June 23rd 2025
Podcast

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

The MARIPOSA trial revealed promising survival benefits with amivantamab plus lazertinib vs osimertinib for patients with EGFR-mutant lung cancer.

MARIPOSA OS Results Are Significant for EGFR+ NSCLC

ONCOLOGY Staff
July 2nd 2025
Article

The MARIPOSA trial revealed promising survival benefits with amivantamab plus lazertinib vs osimertinib for patients with EGFR-mutant lung cancer.

Experts from Washington University in St. Louis discuss dosing considerations and toxicity management strategies for TROP2-targeted ADCs in NSCLC.

Adopting Best Practices for Administering TROP2-Directed ADCs in NSCLC

Daniel Morgensztern, MD;Mary Ellen Flanagan, NP ;Janelle Mann, PharmD, BCOP
June 16th 2025
Podcast

Experts from Washington University in St Louis discuss dosing considerations and toxicity management strategies for TROP2-targeted ADCs in NSCLC.

AI transforms non-small cell lung cancer management, enhancing diagnostics, treatment predictions, and personalized care strategies for improved patient outcomes.

The Role of Artificial Intelligence in Enhancing Precision Medicine for NSCLC

Puneet Modgil, MD
June 24th 2025
Article

AI transforms non-small cell lung cancer management, enhancing diagnostics, treatment predictions, and personalized care strategies for improved patient outcomes.

Developers plan to begin a rolling new drug application for zidesamtinib as a treatment for this non–small cell lung cancer population in July 2025.

Zidesamtinib May Yield Meaningful Outcomes in Advanced ROS1+ NSCLC

Russ Conroy
June 24th 2025
Article

Developers plan to begin a rolling new drug application for zidesamtinib as a treatment for this non–small cell lung cancer population in July 2025.